WO2016191695A3 - Treatments for obligately intracellular infections - Google Patents
Treatments for obligately intracellular infections Download PDFInfo
- Publication number
- WO2016191695A3 WO2016191695A3 PCT/US2016/034686 US2016034686W WO2016191695A3 WO 2016191695 A3 WO2016191695 A3 WO 2016191695A3 US 2016034686 W US2016034686 W US 2016034686W WO 2016191695 A3 WO2016191695 A3 WO 2016191695A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatments
- intracellular infections
- obligately intracellular
- infections
- obligately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided are compositions and methods for treating bacterial infections, such as infections by obligately intracellular bacteria. In some embodiments, a Wnt inhibitor may be administered to a mammalian subject to treat ehrlichiosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562167669P | 2015-05-28 | 2015-05-28 | |
US62/167,669 | 2015-05-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016191695A2 WO2016191695A2 (en) | 2016-12-01 |
WO2016191695A3 true WO2016191695A3 (en) | 2017-01-05 |
Family
ID=56133065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/034686 WO2016191695A2 (en) | 2015-05-28 | 2016-05-27 | Treatments for obligately intracellular infections |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016191695A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019126739A1 (en) | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate anti-cancer therapies |
US20220117920A1 (en) * | 2019-02-14 | 2022-04-21 | University Of Kentucky Research Foundation | N-Aryl Benzenesulfonamides as Protonophores for the Treatment of Cancers, Metabolic Diseases and Traumatic Brain Injury |
CN112933066B (en) * | 2021-02-26 | 2023-05-02 | 河南省农业科学院 | Method for inhibiting porcine reproductive and respiratory syndrome virus in-vitro infection by inhibitor KN-93 and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130323284A1 (en) * | 2012-06-05 | 2013-12-05 | Jazzya Investments | USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION |
-
2016
- 2016-05-27 WO PCT/US2016/034686 patent/WO2016191695A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130323284A1 (en) * | 2012-06-05 | 2013-12-05 | Jazzya Investments | USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION |
Non-Patent Citations (8)
Title |
---|
BAI XIYUAN ET AL: "Inhibition of Nuclear Factor-Kappa B Activation Decreases Survival of Mycobacterium tuberculosis in Human Macrophages", PLOS ONE, vol. 8, no. 4, April 2013 (2013-04-01), XP055293629 * |
DE GROOTE M A ET AL: "The Search For New Antimicrobial Agents Against Mycobacterium abscessus", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, 2012, & 52ND INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC); SAN FRANCISCO, CA, USA; SEPTEMBER 09 -12, 2012, pages F831, XP009191237, ISSN: 0733-6373 * |
DUMLER J STEPHEN ET AL: "Ehrlichioses in humans: Epidemiology, clinical presentation, diagnosis, and treatment", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 45, no. Suppl. 1, 15 July 2007 (2007-07-15), pages S45 - S51, XP002498681, ISSN: 1058-4838, DOI: 10.1086/518146 * |
FLORES R ET AL: "Chlamydia pneumoniae Inclusion Membrane Protein Cpn1027 Interacts with Caprin 2 Enhancing the Canonical Wnt Signaling Pathway", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 110, 2010, & 110TH GENERAL MEETING OF THE AMERICAN-SOCIETY-FOR-MICROBIOLOGY; SAN DIEGO, CA, USA; MAY 23 -27, 2010, pages B - 055, XP055293653, ISSN: 1060-2011 * |
KESSLER MIRJANA ET AL: "Chlamydia trachomatis Disturbs Epithelial Tissue Homeostasis in Fallopian Tubes via Paracrine Wnt Signaling", AMERICAN JOURNAL OF PATHOLOGY, vol. 180, no. 1, January 2012 (2012-01-01), pages 186 - 198, XP055293648 * |
LUO TIAN ET AL: "Ehrlichia chaffeensis Exploits Canonical and Noncanonical Host Wnt Signaling Pathways To Stimulate Phagocytosis and Promote Intracellular Survival", INFECTION AND IMMUNITY, vol. 84, no. 3, March 2016 (2016-03-01), pages 686 - 700, XP009191238 * |
SENDIDE KHALID ET AL: "Cross-talk between CD14 and complement receptor 3 promotes phagocytosis of mycobacteria: Regulation by phosphatidylinositol 3-kinase and cytohesin-1", JOURNAL OF IMMUNOLOGY, vol. 174, no. 7, April 2005 (2005-04-01), pages 4210 - 4219, XP055293620, ISSN: 0022-1767 * |
WAKEEL A ET AL: "New insights into molecular Ehrlichia chaffeensis-host interactions", MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 12, no. 5, 1 May 2010 (2010-05-01), pages 337 - 345, XP027011818, ISSN: 1286-4579, [retrieved on 20100129] * |
Also Published As
Publication number | Publication date |
---|---|
WO2016191695A2 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015114666A3 (en) | Treatments for resistant acne | |
PH12017501646A1 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2013184755A3 (en) | Seca inhibitors and methods of making and using thereof | |
MY173518A (en) | Antimicrobial compounds and methods of making and using the same | |
PH12016502092A1 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2016179440A3 (en) | Antimicrobial therapy | |
PH12016501577A1 (en) | Monobactam organic compounds for the treatment of bacterial infections | |
WO2015148863A3 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
PH12016500453A1 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2017083431A3 (en) | Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections | |
MX2013012165A (en) | Composition and method for enhancing an immune response. | |
NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
MY176900A (en) | Antimicrobial compounds and methods of making and using the same | |
WO2016210384A3 (en) | Bacteria engineered to treat metabolic diseases | |
MX2016010451A (en) | Microbiocidally active benzoxaboroles. | |
WO2019040106A3 (en) | Compounds, salts thereof and their use in the treatment of diseases | |
WO2015110969A3 (en) | Nitrogen containing compounds and their use as antibacterial agents | |
AU2015352440B2 (en) | Compounds | |
EP3268010A4 (en) | Compositions and methods for treating bacterial infection | |
MX2017006674A (en) | Antimicrobial copper compositions and their use in treatment of foodstuffs and surfaces. | |
MX363631B (en) | COMPOSITIONS and METHODS FOR TREATING BACTERIAL INFECTIONS. | |
MY161870A (en) | Antimicrobial compounds and methods of making and using the same | |
WO2013166282A3 (en) | Methods and compositions for treating bacterial infection | |
WO2016191695A3 (en) | Treatments for obligately intracellular infections | |
EP3190893A4 (en) | Compositions and methods for treating and preventing bacterial infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16729696 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16729696 Country of ref document: EP Kind code of ref document: A2 |